

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-71 (canceled).

Claim 72 (previously presented): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises SEQ ID NO: 8, and wherein said composition enhances an immune response in the patient.

Claim 73 (previously presented): The method of claim 72, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 74 (previously presented): The method of claim 73, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 75 (previously presented): The method of claim 73, wherein the non-specific immune response enhancer is an adjuvant.

Claim 76 (previously presented): The method of claim 72, wherein the composition is administered by injection.

Claim 77 (currently amended): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of sequences

having at least 95% identity to SEQ ID NO: 8 and ~~has the same functional properties as SEQ ID NO: 8~~ is able to bind to fibroblast growth factor, and wherein said composition enhances an immune response in the patient.

Claim 78 (previously presented): The method of claim 77, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 79 (previously presented): The method of claim 78, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 80 (previously presented): The method of claim 78, wherein the non-specific immune response enhancer is an adjuvant.

Claim 81 (previously presented): The method of claim 77, wherein the composition is administered by injection.

Claim 82 (previously presented): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising a fusion protein, wherein the fusion protein comprises SEQ ID NO: 8, and wherein said composition enhances an immune response in the patient.

Claim 83 (previously presented): The method of claim 82, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 84 (previously presented): The method of claim 83, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 85 (previously presented): The method of claim 83, wherein the non-specific immune response enhancer is an adjuvant.

Claim 86 (previously presented): The method of claim 82, wherein the composition is administered by injection.

Claim 87 (currently amended): A method for enhancing an immune response in a patient, comprising administering to the patient a composition comprising a fusion protein, wherein the fusion protein comprises a sequence selected from the group consisting of: sequences having at least 95% identity to SEQ ID NO: 8, wherein the sequence ~~has the same functional properties as SEQ ID NO: 8 is able to bind to fibroblast growth factor~~, and wherein said composition enhances an immune response in the patient.

Claim 88 (previously presented): The method of claim 87, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers; and non-specific immune response enhancers.

Claim 89 (previously presented): The method of claim 88, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 90 (previously presented): The method of claim 88, wherein the non-specific immune response enhancer is an adjuvant.

Claim 91 (previously presented): The method of claim 87, wherein the composition is administered by injection.

Claim 92 (new): The method of claim 72, further comprising administering a known immunostimulatory agent, and wherein the isolated polypeptide enhances an immune response to the immunostimulatory agent.

Claim 93 (new): The method of claim 77, further comprising administering a known immunostimulatory agent, and wherein the isolated polypeptide enhances an immune response to the immunostimulatory agent.

Claim 94 (new): The method of claim 82, further comprising administering a known immunostimulatory agent, and wherein the fusion protein enhances an immune response to the immunostimulatory agent.

Claim 95 (new): The method of claim 87, further comprising administering a known immunostimulatory agent, and wherein the fusion protein enhances an immune response to the immunostimulatory agent.